The proportion of patients alive and free of respiratory failure (primary end-point) was numerically greater in the reparixin group, but the difference did not reach statistical significance, possibly due to lower than anticipated mortality in both groups due to changes in population immunity and advancements in therapeutic options for COVID-19, primarily steroids and remdesivir.
← all excerpts
A narrative review of chemokine receptors CXCR1 and CXCR2 and their role in acute respiratory distress syndrome.
1
—
—